The prognosis of pediatric low-grade gliomas is relatively favorable, but unresectable progressive tumors remain a challenge. Chemotherapy including carboplatin-containing regimens can delay the need for radiation therapy in young children. However, hypersensitivity reactions to carboplatin can at times be a severe complication. We have retrospectively evaluated and characterized the hypersensitivity reactions associated with carboplatin administration in pediatric low-grade glioma patients treated on an outpatient basis according to the SIOP/GPOH (International Society of Pediatric Oncology/ Gesellschaft für Pädiatrische Onkologie und Hämatologie) low-grade glioma 1996 protocol, and also reviewed the literature. Of nine patients consecutively treated with carboplatin, seven (78%) developed carboplatin hypersensitivity reactions. The first hypersensitivity reactions (always grade 2) occurred after a median of nine courses (range, 7-12). Although desensitization has been used successfully, there have been reports of severe cases of allergic reaction to carboplatin despite desensitization, including anaphylaxis and death. Since carboplatin hypersensitivity reactions are common and desensitization has not been proven to be safe, efforts should be made to design future therapy protocols for low-grade gliomas with clear guidelines on how to substitute carboplatin when hypersensitivity reactions occur. (J Pediatr Neurol 2004; 2(3): 151-155).
Introduction
Low-grade glial neoplasms are a diverse group of tumors that include pilocytic astrocytoma, fibrillary astrocytoma, oligodendroglioma, ganglioglioma, and mixed tumors as oligoastrocytoma. Their unifying features are their generally slowly evolving, nonaggressive clinical behavior and relatively benign histologic appearance. Generally high rates of long-term survival are characteristic as well, despite low but steady rates of disease progression even after 10 years from diagnosis (1) . Because the developing brain is highly vulnerable to treatment-induced cognitive and endocrine sequelae, particularly from radiotherapy (2-4), contemporary strategies for the management of unresectable or residual progressive childhood low-grade gliomas incorporate age-specific approaches, including chemotherapy. In a large multi-institutional trial of carboplatin and vincristine, 60% of progressive lowgrade glioma patients had a significant reduction in tumor volume, and another 30% of patients had tumor stabilization (5) . A different regimen developed at the University of California at San Francisco included procarbazine, 6-thioguanine, dibromodulcitol, lomustine and vincristine; in children with low-grade gliomas this regimen produced prolonged periods of disease stabilization with a median time to tumor progression of 132 weeks (6) . Chemotherapy effectively postpones the need for radiation, and this delay may reduce neurologic morbidity in children under 5 years of age.
Currently used carboplatin-based chemotherapy regimens for low-grade gliomas can be administered in the outpatient setting, and do not have a high incidence of serious late effects. However, there may be a risk of hypersensitivity reactions which can be life-threatening. In this study we describe the clinical features of carboplatin hypersensitivity reactions in seven patients, and also review the literature.
Materials and Methods
From October 1994 to December 2002, nine patients with unresectable progressive lowgrade gliomas were treated with chemotherapy at the University Children's Hospital of Zurich, Switzerland. Indication to therapy included severe neurologic symptoms at the time of diagnosis (e.g. diencephalic syndrome), progressive clinical symptoms and/or neuroradiologic progression following observation. Three patients had a fibrillary astrocytoma, five a pilocytic astrocytoma and one a low-grade glioma not otherwise specified. Five patients were male and four were female. The median age at diagnosis for these patients was 28 months (range, 5 months to 60 months). Chemotherapy was started 1-72 months after diagnosis. The chemotherapy was applied according to the SIOP/GPOH low-grade glioma 1996 protocol. The first course consisted of vincristine (1.5 mg/ m 2 ) weekly and carboplatin (550 mg/m 2 ; one hour infusion in 200 ml glucose 5% solution) every 3 weeks for 10 weeks. The second course consisted of vincristine and carboplatin every 4 weeks until week 52. All patients received antiemetic ondansetron before carboplatin infusion. During chemotherapy, none of the patients had peritumoral edema requiring oral steroids.
The severity of hypersensitivity reactions was measured according to the National Cancer Institute toxicity scale (7): grade 0, none; grade 1, transient rash, drug fever < 38 o C; grade 2, urticaria, drug fever > 38 o C, mild bronchospasm; grade 3, serum sickness, bronchospasm requiring parenteral medication; grade 4, anaphylaxis.
In case of hypersensitivity reaction to carboplatin grade 1-2, the regimen with carboplatin was continued with close surveillance, premedication with corticosteroids (prednisolone 5 mg/kg), antihistamines (clemastine 0.05 mg/kg) and slowed infusion rate (2 hours). If grade 3-4 reactions occurred, carboplatin was not used thereafter, and substituted with cisplatin (70 mg/m 2 over 6 hours with 24 hour hydration 3000 ml/m 2 ) since cases have been described, where alternative therapy with cisplatin has been successful despite previous hypersensitivity reaction to carboplatin (8) .
Results
The nine patients with progressive lowgrade gliomas received a total of 102 courses of carboplatin. Seven (78%) of nine patients developed hypersensitivity reactions to carboplatin ( Table 1 ). The first hypersensitivity reaction to carboplatin occurred after a median of 9 (range 7-12) chemotherapy courses. In all cases the hypersensitivity reaction occurred during the 1-hour carboplatin infusion. The severity of first hypersensitivity reactions was grade 2 in all We then reviewed the literature and found nine additional articles describing carboplatin hypersensitivity reactions in children (7, (9) (10) (11) (12) (13) (14) (15) (16) . Of a total of 525 children treated with carboplatin, 85 (16%) patients developed hypersensitivity reactions ( Table 2) .
Discussion
Over the past decade, carboplatin has been shown to be one of the most useful and well-tolerated cytotoxic agents available to treat a wide variety of malignancies. Its clinical efficacy in childhood low-grade gliomas is well described, and it is now considered a standard first-line agent against these tumors (17, 18) .
For several reasons, there has been only limited discussion of carboplatin-associated hypersensitivity reactions in the pediatric literature. First, until relatively recently carboplatin was less commonly used than its parent compound, cisplatin. Second, as also demonstrated in this report, hypersensitivity reactions to carboplatin generally do not develop until the patient has received multiple courses of treatment (11, 12, 14, 16, 19) . With the administration of carboplatin as a component of initial chemotherapy and with prolonged use, the incidence of reactions is likely to be considerably greater. Third, it is possible that carboplatin hypersensitivity reactions are not always recognized. In our experience, the early signs can be fairly subtle and may include only a mild rash and a mild bronchospasm. The pathogenesis of the hypersensitivity reaction to carboplatin is still elusive. The clinical features of carboplatin hypersensitivity reactions resemble an IgE-mediated process but follow a more heterogeneous course developing within minutes after initiation of the infusion or near the completion of intravenous infusion or several hours after the drug is delivered. This differs from the typical IgEmediated sensitivity and also intradermal and prick tests to carboplatin appear not conclusive (16) . The symptoms can affect all organ systems, including respiratory (wheezing, dyspnea), gastrointestinal (abdominal cramps, diarrhea), and dermatologic (pruritus, urticaria, facial erythema, and swelling). (20) . Although desensitization has been used successfully in some patients (19, (21) (22) (23) , there have been reports of severe cases of reactions to cisplatin or carboplatin despite desensitization, including anaphylaxis and death (24, 25) . Since carboplatin desensitization has not been proven to be safe, efforts should be made to design future therapy protocols for low-grade gliomas with clear guidelines on how to substitute carboplatin in the event of a hypersensitivity reaction. Several cytotoxic drugs including etoposide, cyclophosphamide and cisplatin, have been shown to have activity in low-grade gliomas and may therefore be used as substitutes for carboplatin.
